Table 1

Baseline characteristics of eligible participants

StudyCountryBaselineNumber of eligible participantsNumber (%) of womenNumber (%) of participants with job strainMean (SD) age at baseline (years)Person-yearsNumber of new type 2 diabetes cases (incidence per 10,000 person-years)Method for diabetes diagnosis*
COPSOQ-IDenmark19971,758855 (49%)358 (20%)40.7 (10.6)20,46744 (21.5)2
COPSOQ-IIDenmark2004–20053,3411,756 (53%)475 (14%)42.6 (10.2)16,57518 (10.9)2
DWECSDenmark20005,5222,581 (47%)1,232 (22%)41.8 (11.0)48,65963 (12.9)2
FPSFinland200046,35637,561 (81%)7,529 (16%)44.5 (9.4)444,9251,175 (26.4)3
GazelFrance199710,8823,049 (28%)1,572 (14%)50.2 (3.0)139,092732 (52.6)4
HeSSupFinland199816,1278,989 (56%)2,824 (18%)39.5 (10.2)112,026129 (11.5)3
IPAWDenmark1996–19971,9881,330 (66%)346 (17%)41.1 (10.4)25,26956 (22.2)2
PUMADenmark1999–20001,8311,514 (83%)276 (15%)42.6 (10.3)18,24624 (13.2)2
SLOSHSweden2006, 200810,6445,771 (54%)2,089 (20%)47.5 (10.8)48,62543 (8.8)2
Still WorkingFinland19869,0792,067 (23%)1,419 (16%)40.9 (9.1)191,416730 (38.1)3
Whitehall IIU.K.1991–19937,0822,140 (30%)946 (13%)48.8 (5.7)89,430558 (62.4)1
WOLF NSweden1996–19984,605767 (17%)587 (13%)43.9 (10.3)53,31148 (9.0)2
WOLF SSweden1992–19955,5932,422 (43%)907 (16%)41.4 (11.0)80,78183 (10.3)2
Total1986–2008124,80870,802 (57%)20,560 (16%)44.1 (9.3)1,288,8223,703 (28.7)
  • *1 = repeated oral glucose tolerance tests complemented by self-report; 2 = mortality and hospitalization registers; 3 = special reimbursement register, mortality, and hospitalization registers; 4 = self-report based on annual surveys and mortality register.